A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110
Authors:
Francesco Di Meo
Anjushree Iyer
Keith Akama
Rujin Cheng
Christina Y. Yu
Annamaria Cesarano
Noriyoshi Kurihara
Hirofumi Tenshin
Arafat Aljoufi
Silvia Marino
Rajesh K. Soni
Julie M. Roda
James Sissons
Ly Vu
Mónica L. Guzmán
Kun Huang
Tamara Laskowski
Hal E. Broxmeyer
David Roodman
Fabiana Perna
Affiliated Authors:
Rajesh K. Soni
Author Keywords:
bcma
bi-specific t cell engager
ccr1
fcrl3
il12rb1
ilt3
immune-targetfinder pipeline
immunotherapy
lrrc8d
mass-spectrometry
multiple myeloma
primary patient samples
sema4a
target antigens
target discovery strategy
validation
Publication Type:
Article
Unique ID:
10.1016/j.xcrm.2023.101110
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: